Premium
A Biocompatible Heterogeneous MOF–Cu Catalyst for In Vivo Drug Synthesis in Targeted Subcellular Organelles
Author(s) -
Wang Faming,
Zhang Yan,
Liu Zhengwei,
Du Zhi,
Zhang Lu,
Ren Jinsong,
Qu Xiaogang
Publication year - 2019
Publication title -
angewandte chemie international edition
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 5.831
H-Index - 550
eISSN - 1521-3773
pISSN - 1433-7851
DOI - 10.1002/anie.201901760
Subject(s) - bioorthogonal chemistry , biocompatibility , drug delivery , chemistry , catalysis , in vivo , combinatorial chemistry , cycloaddition , azide , organelle , nanotechnology , biophysics , click chemistry , materials science , biochemistry , organic chemistry , biology , microbiology and biotechnology
As a typical bioorthogonal reaction, the copper‐catalyzed azide–alkyne cycloaddition (CuAAC) has been used for drug design and synthesis. However, for localized drug synthesis, it is important to be able to determine where the CuAAC reaction occurs in living cells. In this study, we constructed a heterogeneous copper catalyst on a metal–organic framework that could preferentially accumulate in the mitochondria of living cells. Our system enabled the localized synthesis of drugs through a site‐specific CuAAC reaction in mitochondria with good biocompatibility. Importantly, the subcellular catalytic process for localized drug synthesis avoided the problems of the delivery and distribution of toxic molecules. In vivo tumor therapy experiments indicated that the localized synthesis of resveratrol‐derived drugs led to greater antitumor efficacy and minimized side effects usually associated with drug delivery and distribution.